ArticleBMC infectious diseases2025
Cefixime-clavulanic acid in ESBL-producing E. coli lower urinary tract infections: a 13-patient case series.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) represent a substantial proportion of community-acquired infections. The increasing prevalence of Escherichia coli strains that produce extended spectrum beta-lactamases (ESBL) poses a significant obstacle to effective infection treatment. Although carbapenems remain highly effective against ESBL-producing isolates, their use in lower UTIs is limited by the need for intravenous or intramuscular administration, hospitalization, high cost, and the risk of collateral damage due to their broad-spectrum activity. Therefore, there is a growing need for effective oral alternatives.
methodsThis retrospective study evaluated the clinical and microbiological outcomes of 13 patients diagnosed with lower UTIs caused by ESBL-producing E. coli (ESBL-PE), treated with oral cefixime-clavulanic acid (400/125 mg every 12 hours for 14 days). Follow-up urine cultures were obtained on days 3-5 and/or at the end of treatment (days 11-14).
resultsOn days 3-5 of treatment, microbiological and clinical success rates were 53.8% (7/13) and 61.5% (8/13) respectively. At the end of the treatment, urine culture results could be evaluated in 10 cases, microbiological success was 80% (8/10). Clinical success was 84.6% (11/13). Re-infection and relapse rates on day 30 post-treatment were 7.7% (1/13) and 30.8% (4/13), respectively.
conclusionsCefixime-clavulanic acid may be considered an alternative to older antibiotics such as fosfomycin and nitrofurantoin in the treatment of uncomplicated urinary tract infections, and may also contribute to the prevention of carbapenem resistance development. However, these findings should be interpreted with caution due to important limitations, including the small sample size, retrospective design, absence of standardized minimum inhibitor concentration (MIC) testing, and lack of a control group. Larger prospective studies are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.